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Pseudomonas aeruginosa is an opportunistic pathogen causing acute and chronic
respiratory infections associated with morbidity and mortality, especially in patients
with cystic fibrosis. Vaccination against P. aeruginosa before colonization may be a
solution against these infections and improve the quality of life of at-risk patients.
To develop a vaccine against P. aeruginosa, we formulated a novel peptide-based
P. aeruginosa subunit vaccine based on the extracellular regions of one of its major
siderophore receptors, FpvA. We evaluated the effectiveness and immunogenicity of
the FpvA peptides conjugated to keyhole limpet hemocyanin (KLH) with the adjuvant
curdlan in a murine vaccination and challenge model. Immunization with the FpvA-KLH
vaccine decreased the bacterial burden and lung edema after P. aeruginosa challenge.
Vaccination with FpvA-KLH lead to antigen-specific IgG and IgM antibodies in sera,
and IgA antibodies in lung supernatant. FpvA-KLH immunized mice had an increase
in recruitment of CD11b+ dendritic cells as well as resident memory CD4+ T cells
in the lungs compared to non-vaccinated challenged mice. Splenocytes isolated from
vaccinated animals showed that the FpvA-KLH vaccine with the adjuvant curdlan induces
antigen-specific IL-17 production and leads to a Th17 type of immune response. These
results indicate that the intranasal FpvA-KLH conjugate vaccine can elicit both mucosal
and systemic immune responses. These observations suggest that the intranasal
peptide-based FpvA-KLH conjugate vaccine with curdlan is a potential vaccine candidate
against P. aeruginosa pneumonia.
Keywords: FpvA, peptide-based vaccines, Pseudomonas aeruginosa, infection and immunity, vaccine, cystic
fibrosis, mucosal immunity, iron acquisition
Sen-Kilic et al. Peptide-Based FpvA Conjugate P. aeruginosa Vaccine
INTRODUCTION
Pseudomonas aeruginosa is one of the leading opportunistic
Gram-negative pathogens responsible for life-threatening
respiratory infections (1). High adaptability and increasing
prevalence of multidrug-resistant P. aeruginosa poses
a significant threat for at-risk patients (2). People with
compromised immunity, chronic obstructive pulmonary disease,
cystic fibrosis (CF), or those who receive immunosuppressive
therapies are particularly susceptible to P. aeruginosa infections
(1). P. aeruginosa-associated chronic lung infections are one
of the main contributors to loss of pulmonary function, which
is the primary cause of death in patients with CF (3, 4). Based on
the Cystic Fibrosis Foundation 2017 annual report, the median
age at first detection of P. aeruginosa infection is 5.2 years in CF
patients (3). Although eradication is possible early in life, once
the airway of a CF patient becomes chronically colonized, it is
difficult to treat P. aeruginosa infections (5). Therefore, therapies
that prevent or delay the colonization of P. aeruginosa in CF
airways have the potential to increase pulmonary function, and
thus improve the longevity and quality of a CF patient’s life. An
effective vaccine against P. aeruginosa could provide a solution
against infections caused by this bacterium in CF patients, as
well as in other at-risk populations.
Recent efforts in P. aeruginosa vaccine development have
focused on subunit vaccines based on virulence mechanisms of
P. aeruginosa, such as lipopolysaccharide (LPS), flagella, alginate,
and outer-membrane proteins (OMPs) (6). While a number of
these vaccines showed promising results in clinical studies, no
vaccine against P. aeruginosa has been approved for human use
(7). Lack of efficacy has been attributed to serotype variation of
LPS and flagella, as well as to the difficulty of performing clinical
trials in P. aeruginosa at-risk populations (6). Although there is
no vaccine available for clinical use, research efforts focused on
the use of OMPs as vaccine antigens are highly promising. OMPs
are surface-exposed, often more conserved across strains with
varying LPS serotypes, and can be recognized by the immune
system during natural infection, which makes them potential
vaccine candidates (8, 9). In addition, we propose that these
proteins need to be expressed during infection to be relevant
as antigens. In previous studies performed by our laboratory,
we identified P. aeruginosa genes expressed during acute murine
pneumonia (10). From this study, we observed that genes
associated with iron acquisition were significantly up-regulated
in P. aeruginosa during in vivo acute lung infection and decided
to further examine their potential use as vaccine antigens.
Iron is an essential nutrient for P. aeruginosa virulence
and survival in the host (11). During infection, P. aeruginosa
competes for iron with the host using its siderophores and
two other systems for heme uptake (12). Iron availability is
correlated with P. aeruginosa persistence in the lungs of CF
patients (13), and iron acquisition systems are expressed within
CF sputum (14). Each iron acquisition system of P. aeruginosa
includes an outer-membrane receptor located on the surface of
the organism. Therefore, we hypothesize that these receptors
involved in iron acquisition in P. aeruginosa can be used as
antigens to generate a subunit P. aeruginosa vaccine. Among
these receptors, the ferripyoverdine receptor FpvA is involved
in siderophore-mediated iron uptake (15). In addition, our
laboratory observed that the gene encoding this receptor is
highly expressed in vivo during acute murine pneumonia (10).
P. aeruginosa uses FpvA to bind the high-affinity siderophore
pyoverdine to capture iron from the host environment and
translocate it to the cell cytoplasm through a TonB-dependent
system (15). Studies fromWu et al. and Liu et al. have previously
identified and tested FpvA as a potential antigen against P.
aeruginosa (16, 17). FpvA displays numerous characteristics often
associated with protective antigens: (1) FpvA is present on the
surface of the bacterium (18), (2) is expressed during infection
(10, 17, 19), (3) is important for bacterial homeostasis and
virulence (12, 17, 20, 21), and (4) is present in the majority
of P. aeruginosa strains including isolates from CF patients
(22, 23). In addition, iron acquisition receptor-based vaccines
are protective against E. coli, Klebsiella spp., Salmonella enterica
serovar Enteritidis, Neisseria gonorrhoeae, Neisseria meningitidis,
Staphylococcus aureus, and Haemophilus parasuis in different
animal models (24–31). Therefore, the iron acquisition receptor
FpvA has the potential to be used as an antigen against P.
aeruginosa. However, purification of FpvA and maintenance
of the proper folding of the protein during the purification
process is challenging since FpvA is an OMP (17, 32). To
circumvent this problem, we selected smaller peptides based
on the outer-membrane regions of this protein that are more
soluble and may be used as a substitute for the whole protein.
We hypothesize that a peptide-based vaccine containing outer-
membrane regions of FpvA can provide protection against
P. aeruginosa respiratory infections.
In this study, we generated a vaccine containing a cocktail of
peptide antigens based on the outer-membrane regions of FpvA.
These peptides were covalently attached to the carrier molecule
keyhole limpet hemocyanin (KLH) to increase immunogenicity.
Previous studies showed that both Th1 and Th17 associated
immune responses are important to reduce the severity of
P. aeruginosa lung infections (33, 34). Therefore, the vaccine
was formulated with the β-glucan adjuvant curdlan, a known
inducer of Th1/Th17 immune responses (35). In addition,
numerous pathogens, including P. aeruginosa, use mucosal
surfaces as the initial site of entry into the human body
(36, 37). Therefore, having both systemic and mucosal immune
responses against P. aeruginosa is often thought to be crucial
for protection. Intranasal vaccination induces both systemic
and mucosal immune responses in the respiratory tract (38).
Thus, the vaccine was administered intranasally. By performing
vaccination and challenge studies in a murine model of acute
pneumonia, we evaluated the vaccine’s immunogenicity and
protective potential. We determined that intranasal peptide-
based FpvA-KLH conjugate vaccination is effective to decrease
the bacterial burden in the airways and lung edema following
intranasal challenge. We showed that intranasal vaccination with
FpvA-KLH peptides and curdlan as an adjuvant elicits both
systemic and mucosal humoral and cellular immune responses.
Overall, this study supports that in amurinemodel, the intranasal
administration of a peptide-based FpvA conjugate vaccine is
an efficient vaccine strategy against acute pneumonia caused
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by P. aeruginosa and could be pursued as a potential human
vaccine candidate.
METHODS
Bioinformatic Design and Selection of
FpvA Peptide Antigens
Peptides were designed using a multi-step approach: (1) The
crystal structure of the FpvA protein was obtained from the RCSB
ProteinData Bank (PDB) ID:2IAH (39). The extracellular regions
of FpvA were determined from deposited transmembrane
regions in the Orientations of Proteins in Membranes (OPM)
database (40). (2) The protein sequence of FpvA was analyzed
to identify hydrophilic regions based on the Kyte-Doolittle scale
using CLC Genomics Workbench 7.5.1 (41) and to predict linear
B cell epitopes using the BepiPred algorithm (42). Based on the
hydrophilicity and B cell linear epitope prediction, candidate
peptides overlapping with FpvA extracellular regions and with a
length comprised between 20 and 30 amino acids were selected.
(3) The candidate peptides were screened for homology to other
proteins using NCBI-BLASTP (protein-protein BLAST) (43).
Peptides with a percentage of identity higher than 50%, when
compared to non-pathogenic commensal bacteria or human
protein sequences, were excluded from the study to avoid any
undesired cross-species reactivity. (4) Four peptides were selected
and synthesized by Biomatik USA with >85% w/w purity. A
cysteine residue was added on the N-terminus of the peptide
sequence to allow for conjugation to a carrier protein. (5)
Each peptide was conjugated to Keyhole Limpet Hemocyanin
(KLH). The peptides and conjugates were validated using mass
spectrometry and High performance liquid chromatography
(HPLC) by the manufacturer. Chimera 1.10.2 (44) was used to
visualize selected peptides and FpvA protein.
Bacterial Strains
The following strains were used: P. aeruginosa PAO1 “Vasil” (Dr.
Michael L. Vasil, University of Colorado), PAO1 “Washington”
(Dr. Colin Manoil, University of Washington), PAO1 “Spain”
(Dr. Sebastian Alberti, University of the Balearic Islands),
PA14 (Dr. Frederick M. Ausubel, Harvard University), and CF
clinical isolates (45) (Dr. Robert Ernst, University of Maryland).
P. aeruginosa PAO1 “Vasil” strain was used for vaccination
and challenge. P. aeruginosa was grown for 16 h at 37◦C on
Pseudomonas Isolation Agar (PIA) (Becton Dickinson) unless
otherwise specified.
Vaccine Formulation
FpvA and FpvA-KLH peptides were resuspended in 125mM
NaOH (Fisher Scientific). The unconjugated FpvA peptide
vaccine was prepared using a mix of 35 µg of each FpvA peptide
in PBS. The FpvA-KLH conjugate vaccine dose consisted of a
mix of 35 µg of each FpvA-KLH peptide in PBS. The whole-
cell vaccine (WCV) was prepared using P. aeruginosa PAO1
“Vasil.” The strain was grown as described above. Swabbed
bacteria were resuspended in Phosphate Buffered Saline (PBS),
and heat-killed at 60◦C for 1 h. The efficiency of heat-killing was
verified by plating on PIA. Each WCV dose consisted of 4–5
× 107 heat-killed colony-forming unit (CFU) of P. aeruginosa
in PBS. All vaccines were prepared in a final volume of 20 µl
and contained 100 µg of curdlan (Sigma Aldrich) as an adjuvant
unless otherwise specified. The curdlan-only control consisted of
100 µg of curdlan in PBS.
Murine Immunization
Groups of 6-week-old outbred female CD-1 mice (Strain
code:022, Charles River) were anesthetized by intraperitoneal
(IP) injection of a total of 0.2ml of ketamine (7.7 mg/kg)
(Patterson Veterinary) and xylazine (0.77 mg/kg) (Patterson
Veterinary) in 0.9% saline according to the Institutional Animal
Care and Use Committee guidelines. Mice were immunized
intranasally with adjuvant only, unconjugated FpvA peptides,
FpvA-KLH conjugates, or WCV at day 0 followed by a booster
at day 21. The experiments were performed in accordance with
the National Institutes of Health Guide for the care and use
of laboratory animals. The protocols used were approved by
West Virginia University Institutional Animal Care and Use
Committees (WVU-ACUC protocol 1606003173).
Blood Sample Collection
Blood samples were collected from the tail vein or submandibular
vein of each mouse at days 0, 7, 14, and 20 post-vaccination. The
samples were left at ambient temperature for 30min to allow the
blood to coagulate and centrifuged for 2min at 17,900 x g. Serum
was collected and stored at−80◦C.
ELISA
The antibody titers were assayed by ELISA in Costar R© 96
well high-binding microtiter plates (Corning Incorporated). The
microtiter plates were coated with a volume of 50 µl/well of
2 × 107 CFU of heat-killed P. aeruginosa PAO1, 500 ng of
individual FpvA peptides, or a mix of all peptides (125 ng of each
peptide; 500 ng total) overnight at 4◦C. After coating, the plates
were washed three times with PBS with 0.05% Tween 20 (Fisher
Scientific) (PBS-T) and blocked with 2% Bovine Serum Albumin
(BSA) (Bioworld) in PBS overnight at 4◦C. Blocked plates were
washed three times with PBS-T. The samples were prepared in
2% BSA in PBS. The serum samples were serially diluted from
1:50 to 1:25,600, and the lung supernatants were serially diluted
from 1:1 to 1:256. After 1 h of incubation at 37◦C, the plates
were washed four times with PBS-T and incubated with anti-
IgG, -IgM, -IgG1, -IgG2a or -IgG2b, -IgA alkaline-phosphatase
conjugated goat anti-mouse antibodies (SouthernBiotech) at
1:2,000 per well for 1 h at 37◦C. Plates were thenwashed five times
with PBS-T and incubated with Pierce p-Nitrophenyl Phosphate
(PNPP) (Thermo Fisher Scientific) for 30min following the
manufacturer’s instructions. The absorbance of the plates was
read at 405 nm using SpectraMax i3 (Molecular Devices LLC).
Antibody titers were determined as the highest dilution of the
serum with a signal two times above the average of blanks.
To measure the serum IgG response, eleven CF clinical isolates
described by Burns et al. (45), different P. aeruginosa PAO1
strains, and the PA14 strain (46) were grown at 37◦C on minimal
growth mediumM9 (Teknova) overnight. The following day, the
isolates were diluted 1:20 and grown exponentially on M9 media
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until they reached OD600 = 0.25. The Costar
R© 96 well high-
binding microtiter plates (Corning Incorporated) were coated
with 50µl/well of 2× 107 CFU of these cultures. Plates were then
incubated with pooled sera fromNVC and FpvA-KLH vaccinated
challenged mice (1:50 diluted in PBS). Anti-P. aeruginosa
antibodies present in these samples were then detected using
the procedure was done as described above. To characterize the
lung IgA response, PAO1 and CF clinical isolates were grown
and CorningTM 96-well white high-binding microtiter plates
(Corning Incorporated) were coated as described above. Plates
were then incubated with pooled lung supernatants from NVC
and FpvA-KLH vaccinated challengedmice (1:16 diluted in PBS).
For detection, an anti-IgA horseradish peroxidase conjugated
goat anti-mouse secondary antibody (SouthernBiotech) (1:4,000
per well) and the SuperSignalTM ELISA Femto Substrate (Thermo
Fisher Scientific) were used. The chemiluminescence signal
of the plates was detected using Synergy HTX Multi-Mode
Reader (BioTek).
Bacterial Challenge and Respiratory Tissue
Processing at 16h Post-challenge
The bacterial challenge was performed at day 34, and mice
were dissected at 16 h post-challenge. Anesthetized mice were
challenged intranasally with 20 µl of the PAO1 strain (6 × 107
CFU in PBS unless otherwise specified) grown as described
above. As a vehicle control, 20 µl of PBS was administered to the
adjuvant-only group (non-vaccinated non-challenged, NVNC).
Mice were euthanized by IP injection of 390mg pentobarbital/kg
(Patterson Veterinary) in 0.9% NaCl. The blood was collected
by cardiac puncture after euthanasia. The lungs of each mouse
were aseptically removed and weighed. Nares were flushed with
1ml of sterile PBS to collect the nasal washes (NW). Lungs were
homogenized in 1ml of PBS using a glass Dounce homogenizer.
One hundred microliters of homogenized lung samples and NW
from each mouse were then serially diluted and plated on PIA
plates to determine viable CFU counts. To measure the cytokine
response, 200 µl of lung homogenate from each mouse were
pelleted by centrifugation. The lung supernatant was collected
and stored at−80◦C until cytokine analysis. The remaining lung
homogenates were further analyzed by flow cytometry.
Purification of FpvA Protein
The gene fpvAwas amplified by PCR from PAO1 “Vasil” genomic
DNA. Primers were designed to include a SacI restriction site
on the forward primer, and a His6 tag and a HindIII restriction
site on the reverse primer to facilitate cloning and purification
(Table S1). The PCR fragment was first cloned into pCR4-TOPO
(Invitrogen) to generate pCR4-TOPO-fpvA, and resulting clones
were confirmed using Sanger sequencing. pCR4-TOPO-fpvAwas
then digested with SacI and HindIII and ligated into pHERD20T
(47) digested with the same enzymes. Resulting plasmids were
transformed into Escherichia coli strain Clear Coli (Lucigen),
and correct insertion of fpvA in pHERD20T was confirmed by
Sanger sequencing. For protein purification, pHERD20T and
pHERD20TfpvA were grown overnight in Lysogeny Broth (LB,
Miller formulation) supplemented with 100µg/ml carbenicillin
(Fisher Scientific) at 37◦C. Cultures were then diluted 1:100 in
fresh LB and grown for 6 h at 37◦C. Protein expression was then
induced by addition of 0.1% w/v L-arabinose (Sigma-Aldrich)
for 18 to 24 h at 37◦C. Cells were harvested by centrifugation
at 5,000 x g for 10min at 4◦C. Cell pellets were washed with
PBS and centrifuged at 5,000 x g 10min 4◦C. Cells were lysed
for 30min on ice with PBS containing 1mM MgCl2, protease
inhibitors (Halt protease cocktail EDTA free) (Thermo Fisher
Scientific) and 160µg/ml lysozyme (Sigma-Aldrich). Lysates
were then sonicated twice for 30 s on ice and centrifuged at 20,000
x g for 15min at 4◦C. Pellets were solubilized with 1.5% w/v
dodecyl-beta-D-maltoside (MP Biochemicals) in PBS. Samples
were centrifuged 20,000 x g for 15min at 4◦C and supernatants
transferred to HisPur Cobalt columns (Thermo Fisher Scientific).
Elutions were pooled and dialyzed with 10K molecular weight
cut-off SnakeSkin Dialysis Tubing (Thermo Fisher Scientific) in
water overnight at 4◦C. Samples were then concentrated using an
Amicon 50 kDa Nominal Molecular Weight Limit (Millipore).
Protein concentrations were measured using bicinchoninic acid
assay (BCA) total protein kit (Thermo Fisher Scientific).
Western Blot Detection of FpvA-Specific
Antibodies
Five µg of purified FpvA protein were resuspended in Laemmli
buffer (Bio-Rad), boiled for 5min, loaded into each well,
and resolved by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE). Separated proteins were
transferred to a previously rehydrated PVDF membrane (Bio-
Rad). After the transfer, the membrane was blocked with 5% w/v
skim milk (BD Diagnostic Systems) in PBS-T at 4◦C overnight.
The following day, the membrane was incubated with pooled
murine sera from the FpvA-KLH (n = 5) and NVC (n = 5)
groups at a dilution of 1:2,000, or with anti-His antibodies
(Proteintech Group) at 1:5,000 in 5% w/v skim milk in PBS-T
for 16 h. The membrane was washed three times with PBS-T
and incubated with anti-mouse IgG antibodies conjugated with
HRP (Immunoreagents) at 1:5,000 in 5% w/v skim milk in
PBS-T for 1 h. The membrane was rewashed three times with
PBS-T and finally developed using SuperSignal West Femto
Maximum Sensitivity Substrate (Thermo Fisher Scientific).
Chemiluminescence signal was detected using a Chemidoc
Touch Imaging System (Bio-Rad).
Opsonophagocytic Killing Assay
P. aeruginosa PAO1 was grown in 5ml of LB overnight. The
following day, the suspension was diluted at 1:100 dilution in
fresh LB and exponentially grown to OD600 = 0.3. The cells
were pelleted and re-suspended in 5ml of minimal essential
medium (MEM) (Corning Incorporated) with 1% BSA (MEM-
BSA) (Bioworld). The suspension was diluted in MEM-BSA to
obtain a final concentration. J774A.1 macrophages (ATCC) were
grown in DMEM medium (Corning Incorporated), harvested
and resuspended in MEM-BSA. Mice sera from NVNC, WCV,
and FpvA-KLH groups were used for opsonophagocytic assays at
a concentration of 2x the titer for anti-P. aeruginosa antibodies
for each serum. Sera of each group were incubated for 30min
at 56◦C to inactivate complement activity. P. aeruginosa PAO1
(2.5 × 105 CFU/ml), macrophages (2.5 × 105 cells/ml), and
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serum sample were incubated together in microcentrifuge tubes
by tumbling end-over-end on a rotator at 37◦C for 1.5 h. As
control, the same amount of NVNC control serum was used for
each WCV and FpvA-KLH serum sample. After the incubation
period, samples were serially diluted and plated on PIA. The
percentage of bacterial killing was calculated by comparing the
number of bacteria killed in samples incubated with WCV or
FpvA-KLH sera to the NVNC control serum. The percent killing
was calculated relative to NVNC control serum. Percent Kill =
[{(CFU counts from the same amount of NVNC serum) – (CFU
counts from vaccinated challenged serum)}/(CFU counts from
the same amount of NVNC serum) × 100]. Serum from each
mouse was evaluated using technical duplicates.
Hematologic Analysis
To measure the number of white blood cells in blood upon
challenge, 200 µl of blood were collected into BD Microtainer R©
Blood Collection Tubes (BD Biosciences). Blood samples
were analyzed immediately using an Hemavet 950 FS (Drew
Scientific). The results were compared to a mouse blood standard
(Drew Scientific).
Flow Cytometry Sample Preparation and
Analysis
Flow cytometry was performed on lung and spleen samples. Lung
samples were prepared as described above. Lung homogenates
were diluted with 4ml of PBS and the suspension was strained
using a 100µm pore cell strainer (VWR International). The
spleens frommice challenged with 107 CFU were collected at day
7 post-challenge, diluted with 4ml RPMI 1640 medium (Thermo
Fisher Scientific) with 10% v/v fetal bovine serum (FBS) and
0.5% w/v penicillin-streptomycin (Corning) (RPMI complete
medium), and homogenized gently through a disposable 100µm
pore cell strainer. Samples were centrifuged at 1,000 x g for
5min, and supernatants were removed. Red blood cells were
lysed using Pharm Lyse (BD Biosciences) for 2min at 37◦C.
The remaining cells were centrifuged at 1,000 x g for 5min.
The pellets were resuspended in PBS with 1% v/v FBS for Fc
receptor blocking and incubated on ice for 15min. Lung cells
were stained with myeloid and resident memory cell surface
markers (Table S2). Each cell suspension sample was incubated
with the antibody cocktails for 1 h at 4◦C in the dark. Cell
suspension samples were pelleted and resuspended in PBS.
Spleen cells were stained with specific T cell surface markers and
intracellular transcription factor markers using PharmingenTM
Transcription Factor Buffer (BD Biosciences) (Table S2). The
cell surface staining was performed as described above. The
cells were then pelleted, fixed, and permeabilized with 1ml of
Fix/Perm buffer (BD Biosciences) for 50min at 4◦C. The fixed
and permeabilized cells were washed with 1ml of Perm/Wash
buffer (BD Biosciences) twice before intracellular staining for
50min at 4◦C in the dark. Cell suspension samples were
pelleted, washed with Perm/Wash buffer and resuspended in
PBS. Samples were processed using a LSR Fortessa flow cytometer
(BD Biosciences) and analyzed using FlowJo v10 (FlowJo, LLC).
The flow cytometry gating strategy for myeloid cells was adapted
fromMisharin et al. (48) (Figure S1).
Cytokine Analysis
To measure the cytokine response, the concentration of IFN-γ,
IL-1β, IL-2, IL-4, IL-5, IL-6, KC/GRO, IL-10, IL-12p70, TNF-
α, and IL-17 in the lung were determined by quantitative
sandwich immunoassays using the Meso Scale Diagnostics V-
PLEX Plus Proinflammatory Panel 1 Mouse Kit (K15048G-1)
and Mouse IL-17 Ultra-Sensitive kits (K152ATC-1), following
the manufacturer’s instructions. The electrochemiluminescence
signal was detected using the MSD Multi-Array Imaging
Platform (Meso Scale Diagnostics). Lung supernatants from
NVNC, NVC, and FpvA-KLH groups were diluted 1:5 and 1:300
to avoid saturation of the signal.
ELISpot
ELISpot assays were performed to determine the number of
antigen-specific splenocytes in vaccinated animals secreting IL-
17 and IFN-γ in response to antigen stimulation. For these
experiments, a FpvA-KLH vaccine was also formulated with a
mixture of 35 µg of each FpvA-KLH peptide and 62.5 µg of
alhydrogel (Invivogen) in PBS. EMD Millipore Multiscreen 96-
well assay (Thermo Fisher Scientific) plates were pre-wetted with
15 µl of 35% v/v ethanol for 1min. The plates were washed five
times with 200 µl of sterile water and coated with anti-IL-17
(5µg/ml) (Mabtech) and anti-IFN-γ (5µg/ml) (BD Biosciences)
antibodies overnight at 4◦C. Splenocytes were isolated from
immunized and boosted CD-1 mice as described above. The
spleen of each mouse was collected at day 34 and homogenized
using a 100µm sterile cell strainer (VWR International). The
splenocytes were counted using trypan blue (Life Technologies)
with a Countess II FL Automated Cell Counter (Invitrogen).
The cells were diluted to 106 cells/ml using RPMI complete
medium. The splenocytes were then aliquoted in duplicate
and incubated with RPMI complete medium only, or RPMI
complete medium containing 107 heat-killed P. aeruginosa using
pre-wetted, antibody-coated plates. The splenocytes from non-
vaccinated control mice were also incubated with RPMI complete
medium containing 50 ng/ml Phorbol 12-myristate 13-acetate
(PMA) (Fisher Scientific) as a positive stimulant control. IL-
17 antibody-coated plates were incubated for 72 h and IFN-γ
antibody-coated plates were incubated for 16 h at 37◦C with
5% CO2. After the incubation, the wells were washed and
incubated with biotinylated anti-IL-17 (0.25µg/ml), or anti-IFN-
γ (2µg/ml) secondary antibodies for 2 h at room temperature
according to the manufacturer’s instructions. The wells were
then rewashed, incubated with streptavidin-alkaline phosphatase
(Mabtech) for 1 h at room temperature, and developed using
a filtered substrate solution of BCIP/NBT (Mabtech). ELISpot
plates were imaged using an Olympus MVX10 Microscope. The
images were processed with FFT Bandpass filter, converted to
binary images and counted automatically for particles bigger than
10 pixel2 using Image J software v.1.52a (49).
Histological Analysis
For these experiments, mice were vaccinated as described above
and challenged with 2 × 108 CFU of P. aeruginosa PAO1. The
lungs were collected from vaccinated mice at 16 h post-challenge,
perfused, and fixed with 4% v/v formalin (Fisher Scientific).
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FIGURE 1 | Vaccine design and selection of the FpvA peptides. (A) Schematic representation of the FpvA peptide design process. (B) Structure of FpvA protein (gray)
bound to pyoverdine (ocean green) (PDB ID: 2IAH). The peptides used in this study are highlighted in yellow. (C) Peptide sequences and amino acid residue numbers
of the selected FpvA peptides.
The samples were sectioned and stained with hematoxylin and
eosin (H&E) by the WVU Pathology Department. A total of 10
images per 2 slides in each group were imaged at 10x and 40x
magnification on an EVOS XL Cell Imaging System (Thermo
Fisher Scientific).
Statistical Analysis
All statistical analyses were performed using the software Prism
version 7 (GraphPad). Comparisons between two groups were
performed using an unpaired Student’s t-test. Comparisons
between three or more groups were analyzed by one-way analysis
of variance (ANOVA) followed by a Tukey’s multiple comparison
test for data that follows a normal distribution. Statistical analysis
for non-parametrical data was performed using the Kruskal-
Wallis test with Dunn’s multiple comparison test. For statistical
analysis of non-parametric samples for which no signal was
detected (i.e., NVNC and NVC serum titers), comparisons
were made to the hypothetical value of 1 using a Wilcoxon
signed-ranked test to compare the antibody titer responses. One
sample t-test was used for comparison of opsonophagocytic
killing assays.
RESULTS
FpvA-KLH Peptide Vaccination Leads to
FpvA-Specific Antibody Production in a
Murine Model of Vaccination
To develop a vaccine against P. aeruginosa using the OMP FpvA,
we designed and selected peptides based on the outer-membrane
regions of the protein. The workflow of peptide design is
shown in Figure 1A. The selected peptides were synthesized and
conjugated to the carrier protein, keyhole limpet hemocyanin
(KLH), to increase their immunogenicity. Peptide position and
sequence information are shown in Figures 1B,C.
To determine the immunogenicity of the peptides, we
formulated them as vaccines with the adjuvant curdlan (16).
We used P. aeruginosa heat-inactivated whole cell vaccine
(WCV) with curdlan as a positive control. Curdlan alone
(non-vaccinated challenged, NVC) was used as vehicle control.
Cocktails of unconjugated FpvA peptides, FpvA-KLH peptide
conjugates, and control groups were intranasally administered
to 6-week-old female CD-1 mice (Figure 2A). To determine
the immunogenicity of each vaccine, IgG and IgM levels
were measured over time. Using this experimental design,
we observed as expected that our positive control WCV led
to an increase in the production of anti-P. aeruginosa IgM,
followed by a class-switch to IgG over time (Figure 2B). The
unconjugated FpvA peptides elicited low anti-FpvA peptide-
specific IgM antibody titers that did not result in significant
isotype switching to IgG (Figure 2C). This suggests that the
unconjugated FpvA peptides are poorly immunogenic and fail
to induce a significant IgG antibody response over time. In
the FpvA-KLH vaccinated mice, we observed a significant
production of anti-FpvA peptide-specific IgM antibodies. In
addition, we observed isotype switching to IgG in the FpvA-
KLH group (Figure 2D). We also observed that mice immunized
with the FpvA-KLH vaccine resulted in significant increase in
anti-FpvA peptide-specific IgG compared to unconjugated FpvA
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FIGURE 2 | Experimental design and antibody responses over time. (A) Schematic diagram of the vaccination timeline and overall experimental design. Mice were
vaccinated with FpvA peptides, FpvA-KLH conjugates, WCV or adjuvant only (NVNC) and received a booster of the same vaccine at day 21. Mice were challenged
with P. aeruginosa PAO1 by intranasal instillation at day 34. IgG and IgM anti-PAO1 antibodies in WCV vaccinated mice (n = 14) (B), anti-unconjugated FpvA peptide
antibodies in FpvA-vaccinated mice (n = 13) (C), or in FpvA-KLH vaccinated mice (n = 14) (D) collected at day 7, day 14, day 20, and day 35. No antibody response
was detected in NVNC animals, the comparisons were made to the hypothetical value of 1 using Wilcoxon signed-ranked test. The asterisks refer to statistical
significance: **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.001. Error bars are mean ± SEM values.
peptides at day 35 post-vaccination (1,000-fold) (Figure 3A).
Compared to the NVC group, immunization with FpvA-KLH
lead to the significant production of anti-FpvA peptide-specific
IgG and IgM (Figure 3A). While the mice were immunized with
a mix of four FpvA peptides conjugated to KLH, anti-peptide
2 antibodies accounted for most of the IgG serum titers, and
anti-peptide 4 antibodies were detected in three out of nine
mice (Figure S2).
We observed that vaccination with FpvA-KLH could induce
an antibody response that recognizes the FpvA peptides.
However, this response is unlikely to be protective if these
antibodies do not recognize the FpvA protein or the whole
bacterium. To determine if antibodies generated by vaccination
with FpvA-KLH could recognize the full-length protein, we
performed Western blot analysis with the purified recombinant
FpvA protein. The results indicate that the serum from FpvA-
KLH vaccinated mice, but not NVC mice, recognizes the
purified recombinant FpvA protein (Figure 3B). Finally, we
tested whether the antibodies elicited by FpvA-KLH vaccination
could recognize the whole bacteria. We detected a significant
amount of IgG and IgM against P. aeruginosa PAO1 in the
FpvA-KLH vaccinated mice compared to NVC (Figure 3C).
Similar to the data obtained in Figure 3A, conjugation of the
peptides with KLH resulted in significant increase in IgG (100-
fold) and in IgM antibody response (10-fold) compared to the
unconjugated FpvA peptides (Figure 3C). Immunization with
the unconjugated FpvA peptides did not produce a significant
antibody response against P. aeruginosa PAO1 compared to
NVC (Figure 3C).
To characterize whether sera from FpvA-KLH vaccinated
mice could recognize other P. aeruginosa strains, we performed
ELISA experiments with 11 P. aeruginosa clinical isolates
from the sputum and bronchoalveolar lavage of CF patients
(45). We compared the serum IgG response to various P.
aeruginosa laboratory-adapted strains, including different P.
aeruginosa PAO1 and PA14 strains (46). The data obtained
indicate that the serum from FpvA-KLH peptide-vaccinatedmice
can bind to CF isolates as well as the lab strains above the
background threshold, suggesting that these antibodies can also
recognize clinical P. aeruginosa isolates (Figure 3D). These data
indicate that vaccination with FpvA-KLH peptides triggers the
production of antibodies that recognize the unconjugated FpvA
peptides, purified recombinant FpvA protein, as well as different
P. aeruginosa strains.
Finally, to determine the role of these antibodies in
bacterial killing, we performed opsonophagocytosis assays using
murine macrophage J774A.1 cells. Both FpvA-KLH (33.9%
killing) and WCV (72.7% killing) sera significantly increased
opsonophagocytosis of P. aeruginosa PAO1 compared to sera
from naïve animals (Figure 3E). These data show that antibodies
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FIGURE 3 | Antibodies elicited by FpvA-KLH peptide vaccination can recognize the FpvA peptides, FpvA protein, and P. aeruginosa. (A) IgG and IgM antibody titers
of NVC, FpvA peptides only, and FpvA-KLH vaccinated and challenged groups. Unconjugated FpvA peptides were used as antigen. (B) Western blot analysis of
pooled NVC and FpvA-KLH (n = 5) sera against purified FpvA protein expressed in E. coli using the vector pHERD20TfpvA-His6. pHERD20T is used as a vehicle
control. (C) IgG and IgM antibody titers of NVC, FpvA peptides only and FpvA-KLH vaccinated and challenged groups. Heat-killed whole-cell P. aeruginosa PAO1 was
used as antigen. In (A,C), each circle represents data from one mouse of NVC (n = 14), WCV (n = 14), FpvA (n = 13), and FpvA-KLH (n = 14) vaccine groups. Data
points represent the mean of three independent experiments. The p-values were calculated using a Kruskal Wallis test with Dunn’s multiple comparison test. (D) IgG
response of pooled sera from NVC and FpvA-KLH vaccinated challenged mice using P. aeruginosa cystic fibrosis isolates (n = 11) and lab strains (PAO1 and PA14) (n
= 4) as antigens. Each circle represents different P. aeruginosa strains, triangles show the PAO1 strain used for infection. The p-values were calculated using unpaired
Student’s t-test. All data represent titers collected at 16 h post-challenge. (E) Percentage of opsonophagocytic killing activity of FpvA-KLH and WCV sera against P.
aeruginosa PAO1. Percentage was calculated relative to NVNC control. The p-values were calculated using a one-sample t-test. The asterisks refer to statistical
significance: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Error bars are mean ± SEM values.
generated by FpvA-KLH can mediate opsonophagocytosis
in vitro and could potentially participate in bacterial clearance
during infection.
FpvA-KLH Vaccination Reduces the
Bacterial Burden and Pulmonary Edema
During Acute Pneumonia Caused by
P. aeruginosa
To evaluate whether FpvA-KLH vaccination conferred
protection against P. aeruginosa, mice were challenged on
day 34 (Figure 2A). The bacterial burden in the nares and the
lung were determined by plating the serial dilutions and counting
viable bacteria at 16 h post-challenge. As expected, the bacterial
load in the airways of the WCV mice was significantly lower
than in NVC. Vaccination with FpvA-KLH resulted in decreased
bacterial burden in nasal cavities and lung compared to the
NVC control group (p = 0.0028 and p = 0.0061, respectively)
(Figures 4A,B). This decrease was not significantly different
between FpvA-KLH and WCV vaccinated mice, indicating that
these mice are similarly protected against colonization in the
lungs and nares. When the mice were vaccinated KLH alone,
we did not observe any decrease in bacterial burden (data not
shown). These results suggest that protection is conferred by
the conjugation of the FpvA peptides to KLH and not KLH
alone. Overall, vaccination with FpvA-KLH peptides leads to
a significant decrease in the bacterial burden during acute
P. aeruginosa pneumonia.
P. aeruginosa causes pneumonia associated with acute lung
injury, inflammation, and pulmonary edema during infection
(50, 51). We hypothesized that FpvA-KLH could help alleviate
these pathologies. As an indicator of lung edema, we measured
the wet weights of the lung from the infected mice. To observe
pulmonary damage and inflammation, we performed lung
histopathological analysis. The lung weight of mice vaccinated
with FpvA-KLH was significantly decreased compared to the
NVC mice after challenge. There were no significant differences
in the lung weight between the FpvA-KLH vaccinated, NVNC,
and WCV groups (Figure 4C). The body weight of mice was
not significantly different in any of the groups (Figure S3),
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FIGURE 4 | FpvA-KLH vaccination decreases bacterial burden and pulmonary edema in mice challenged with P. aeruginosa. The bacterial burden of NVC (n = 8),
WCV (n = 10), and FpvA-KLH (n = 8) vaccinated mice in the nasal wash (A) and lung (B). (C) Lung weight of vaccinated and challenged mice. The NVNC (n = 10)
group was used as a control. Each circle represents data from one mouse. Data represent two independent experiments. The p-values were calculated using ANOVA
followed by a Tukey’s multiple-comparison test. Error bars are mean ± SEM values. The asterisks refer to statistical significance: **p ≤ 0.01, ***p ≤ 0.001,
****p ≤ 0.0001. (D) H&E staining of lungs from immunized and adjuvant only control mice. Representative histopathological sections are shown (magnification = 10x
and 40x). All data shown were collected at 16 h post-challenge.
which suggests that the differences observed in lung weights
are not associated with differences in overall body mass.
In addition, the FpvA-KLH and WCV vaccinated mice had
a lower recruitment of polymorphonucleated cells compared
to NVC (Figure 4D). These data indicate that FpvA-KLH
vaccination prevents the increase in pulmonary edema and
recruitment of polymorphonucleated cells associated with P.
aeruginosa infection. Altogether, these results show that FpvA-
KLH vaccination reduces the bacterial burden in the lung and
nares as well as lung damage and inflammation.
Effect of FpvA-KLH Vaccination on the
Cytokine and Myeloid Cell Response
Myeloid cells are crucial in the initial phase of infection.
These cells participate in phagocytosis, antigen presentation,
recruitment of other immune cells to the site of infection
through cytokine secretion, and assist in inducing an adaptive
immune response (52, 53). To understand how the FpvA-
KLH vaccination mediates protection against P. aeruginosa, we
characterized the immune response at 16 h post-challenge. We
first measured the cytokines present in the lung. We observed
that the amount of IL-17, IL-12, IL-5, IFN-γ, TNF-α, IL-
1β, and IL-10 in the lung supernatant significantly increased
in all challenged groups compared to non-challenged control
mice (Figure S4, Table S3). However, there was no significant
difference in cytokine secretion between the challenged groups,
regardless of the vaccine they received (Figure 5A, Figure S4
and Table S3). From these experiments, we concluded that
cytokine measurement during acute P. aeruginosa lung infection
is insufficient to identify differences in the immune response of
vaccinated and non-vaccinated mice in this model.
To gain further insights into the type of immune response
mounted upon FpvA-KLH vaccination, wemeasured the number
of circulating white blood cells and performed flow cytometry
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FIGURE 5 | Innate immune responses in lungs at 16 h post-challenge. (A) Logarithmic average of overall cytokine responses in lung supernatant of NVNC, NVC, and
FpvA-KLH vaccinated mice represented using a spider graph. The vertical axis shows the log scale increase of averaged cytokine response (pg/ml). (B) Representative
contour plots of the NVNC (n = 5), NVC (n = 6), and FpvA-KLH (n = 4) groups showing the gating strategy for CD11b+GR-1hi (neutrophils) and CD11b+GR-1lo cell
populations in lung leukocytes. (C) Proportion of CD11b+GR-1hi and CD11b+GR-1lo in lung leukocytes from (B). Group comparisons were analyzed by ANOVA
followed by a Tukey’s multiple-comparison test. (D) Representative histograms show proportion of MHCII+ cells in CD45+SiglecF−GR-1lo/−CD11b+ cell populations.
(E) MHCII+CD45+SiglecF+/−GR-1lo/−CD11b+ cell proportions of lung leukocytes. Subpopulations are separated as the proportion of CD11b+ dendritic cells
(CD45+SiglecF+/−GR-1lo/−CD11b+CD64−CD24+) and interstitial macrophages (CD45+SiglecF+/−GR-1lo/−CD11b+CD64+CD24−) and other MHCII+ cells were
shown. Group comparisons were analyzed by ANOVA followed by a Tukey’s multiple-comparison test for MHCII+CD45+SiglecF+/−GR-1lo/−CD11b+ cell population.
The asterisks refer to statistical significance: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
on lung single cell suspensions. We did not observe any
differences in total white blood cells counts, or in the proportion
of monocytes and neutrophils in blood (Figures S5A–C).
However, we observed a significant increase in the percentage of
eosinophils in the blood samples of the NVC group compared
to NVNC and FpvA-KLH groups (Figure S5D). Interestingly, we
detected opposite trends in the lung. First, we observed that the
number of both CD11b+GR-1hi (neutrophils) and CD11b+GR-
1lo myeloid cells increased in NVC and FpvA-KLH groups
compared to the NVNC mice group (Figures 5B,C). However,
we did not observe any significant changes between NVC and
FpvA-KLH vaccinated groups (Figure 5C). In addition, while
the proportion of eosinophils was increased in blood of NVC
group, it was not significantly different in the lung samples
of NVC, NVC, and FpvA-KLH (Figures S5D, S6A). Also, there
were no significant differences in the proportion of lung alveolar
macrophages between any of the challenged groups (Figure S6B).
FpvA-KLH Vaccine Stimulates the
Recruitment of Antigen-Presenting Cells to
the Site of Infection
CD11b+ cells are of particular interest during vaccination and
challenge as they include professional antigen presenting
cells (APCs), which are crucial in the establishment of
an adaptive immune response. To further determine the
effect of the FpvA-KLH vaccination on MHCII+ CD11b+
cell population in the lungs, we used the gating strategy
shown in Figure S1. We observed that MHCII+ cells
in the CD45+SiglecF+/−GR1lo/−CD11b+ myeloid cell
population were increased more than 2-fold in the FpvA-KLH
vaccinated and challenged mice compared to NVC and NVNC
(Figures 5D,E). Within this population, CD11b+ dendritic
cells (CD45+SiglecF+/−GR-1lo/−CD11b+CD64−CD24+) were
the major cell type increased in the FpvA-KLH vaccinated
group compared to NVNC and NVC (Figure 5E and
Figure S6C). There were no significant differences in the
proportion of interstitial macrophages (CD45+SiglecF+/−GR-
1lo/−CD11b+CD64+CD24−) between any of the challenged
groups (Figure S6D). Overall, these results suggest that
FpvA-KLH vaccination increases the recruitment of
CD45+SiglecF+/−GR-1lo/−CD11b+MHCII+ myeloid cells
to the lung upon challenge, and the majority of these cells are
CD11b+ dendritic cells.
Intranasal FpvA-KLH Vaccine With Curdlan
Induces a Th17 Immune Response
Th1 and Th17 specific immune responses were previously
shown to decrease the severity of pneumonia caused by P.
aeruginosa and are required to mount an adaptive immune
response against this pathogen (33, 34). To characterize the type
of CD4+ T cell response elicited by FpvA-KLH vaccination,
we first identified the presence of IgG2 and IgG1 isotypes
as surrogate markers of Th1 and Th2 immune responses,
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respectively. We observed the presence of FpvA peptide-specific
IgG1 and IgG2 antibodies in the serum (Figure 6A). FpvA
peptide-specific IgG2b antibodies were detected in all sera of
FpvA-KLH vaccinated mice, while we detected IgG2a only in
some of them (8/14) (Figure 6A). Interestingly, we did not
observe any increase in the percentage of Th1 (CD4+Tbet+)
or Th2 cells (CD4+GATA3+) in the splenocytes of FpvA-KLH
vaccinated and challenge groups compared to NVNC or NVC
at day 7 post-challenge (Figure 6B). However, we observed a
significant increase in the Th17 (CD4+RORγT+) cell population
in the FpvA-KLH vaccinated mice compared to both NVC
and NVNC mice groups (Figure 6C). These data suggest that
FpvA-KLH vaccination with curdlan leads to a Th17 cellular
immune response.
To evaluate whether the elicited cellular immune response is
antigen-specific, we performed IFN-γ and IL-17 ELISpot assays
using splenocytes. In the mice vaccinated with curdlan alone
or FpvA-KLH with curdlan, we did not observe any difference
in IFN-γ secreting cells in response to stimulation with P.
aeruginosa (Figure S7). On the other hand, splenocytes from
FpvA-KLH vaccinated mice had a significantly higher number
of IL-17 secreting cells than those immunized with curdlan
alone in response to stimulation with P. aeruginosa (Figure 6D).
Previous studies have shown that the adjuvant curdlan is an
inducer of Th17 immune responses (35, 54). To determine
whether the increase in the Th17 response is due to the inclusion
of the FpvA-KLH peptides or the adjuvant, we re-formulated
the FpvA-KLH vaccine with alum adjuvant. We observed that
the FpvA-KLH vaccine adjuvanted with alum was not able to
induce a significant increase in IL-17 producing cells in response
to heat-killed P. aeruginosa compared to unstimulated control
(Figure 6D). These results may indicate that both the adjuvant
curdlan combined with the FpvA-KLH antigen are necessary to
induce IL-17 secretion in splenocytes.
Induction of Mucosal Memory Immune
Response by Intranasal FpvA-KLH
Vaccination
Previous studies have shown that upon intranasal vaccine
administration, IgA (38) and tissue-resident memory response
can be elicited (55). These responses play an essential role in
protecting against respiratory bacterial pathogens. Therefore, we
hypothesized that intranasal vaccination with FpvA-KLH could
induce a humoral mucosal immune response via IgA secretion
as well as a tissue-resident memory response in upper airways.
Mice vaccinated intranasally with FpvA-KLH had significant IgA
titers against FpvA peptides compared to NVC mice in lung
supernatants (Figure 7A). In addition, these IgA antibodies were
able to bind significantly to different lab-adapted and CF P.
aeruginosa isolates (Figure 7B). To determine whether FpvA-
KLH vaccination also increased the recruitment of memory T
cells to the lung, we performed flow cytometry. The contour plots
show the gating strategy in NVNC, NVC, and FpvA-KLH groups
to identify naïve CD4+ T cells (TN) (CD4
+CD44−CD62L+), T
effector memory-like cells (TEM) (CD4
+CD44+CD62L−) and
T central memory cells (TCM) (CD4
+CD44+CD62L+) within
CD4+ T cell population (Figure 7C). We observed that the
proportion of naïve CD4+ T cells was decreased in FpvA-KLH
vaccinated mice compared to NVNC (Figure 7D). While there
are fewer naïve CD4+ T cells, we observed that the proportion
of T effector memory-like cells (TEM) but not T central
memory cells (TCM) (CD4
+CD44+CD62L+) was significantly
increased in the FpvA-KLH group compared to NVC and NVNC
(Figure 7E). Among the T-effector memory-like cell population,
the percentage of CD103+CD69+ cells (Figure 7F), which are
known to have a tissue-resident memory phenotype (TRM)
(55), was significantly increased in the FpvA-KLH vaccinated
mice compared to NVNC and NVC (Figure 7G). Overall, the
intranasal FpvA-KLH vaccine can induce mucosal IgA, as well
as a tissue-resident memory T cell response in the lung. These
results suggest that intranasal vaccination with FpvA-KLH elicits
both humoral and cellular mucosal immune responses.
DISCUSSION
The ferripyoverdine receptor FpvA, is one of the main iron
acquisition receptors of P. aeruginosa (15). It is essential for
virulence and homeostasis, is expressed during infection, and
is known to be antigenic (10, 12, 17, 19–21). In this study, we
explored if a vaccine containing peptides based on the outer-
membrane regions of FpvA could be protective against acute
P. aeruginosa pneumonia in mice. We demonstrated that the
FpvA peptides conjugated to the carrier protein KLH can induce
both cellular and humoral immune responses and can provide
protection against P. aeruginosa acute pneumonia in mice.
Peptide-based vaccines have been shown to be protective
against both bacterial and viral pathogens in animal models
(56). They can provide solutions with minimal cross-reactivity or
reactogenicity in patients, as the type of response they trigger can
be more finely controlled (57). Due to their small size, peptides
are usually weakly immunogenic without carrier molecules to
induce a robust immune response (56, 58). As expected, we
observed that the FpvA peptides used in this study were more
immunogenic when conjugated to the carrier protein KLH.
Overall, antibodies secreted in response to the FpvA peptides
conjugated to KLH were able to recognize the unconjugated
FpvA peptides, the full-length FpvA protein, as well as whole
bacteria in vitro. These data suggest that while we used short and
linear antigen sequences for vaccination, the FpvA-KLH peptides
were sufficient to provide a response that would also recognize
the full protein and the bacteria.
Previous studies have identified the FpvA protein as a
potential protective vaccine antigen for P. aeruginosa (16, 17).
In an earlier study, purified FpvA protein adjuvanted with
curdlan administered intranasally could produce antigen-specific
antibody responses but failed to protect against P. aeruginosa
(17). In this study, while we expressed and purified the FpvA
protein in E. coli, we chose not to pursue its use as an antigen
due to difficulties in purification and low solubility. Smaller
peptides based on the outer-membrane regions of OMPs are
more soluble and can be used as a substitute for the whole
protein. In addition, biological impurities from purified OMPs,
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FIGURE 6 | Quantification of the T cell immune response. (A) Elicited IgG subtypes (IgG1, IgG2b, and IgG2a) of FpvA-KLH vaccinated sera using the unconjugated
FpvA peptides as antigen. Each circle represents data from one mouse. Data represent three independent experiments combined. P-values were calculated by
comparing data to hypothetical value of 1, using a Wilcoxon signed-ranked test. Error bars are mean ± SEM values. In (B,C), splenocytes were isolated from NVNC (n
= 5), NVC (n = 8), and FpvA-KLH (n = 5) vaccinated groups 7 days post-challenge. (B) CD4+T-bet+ (Th1) and CD4+GATA3+ (Th2) cell proportions in the spleen. (C)
Proportion of CD4+RORγT+ (Th17) cells in the spleen. (D) ELISpot assay with splenocytes to identify IL-17 specific response of each group in the presence or
absence of heat-killed P. aeruginosa at day 34 (n = 5 in each group). Phorbol 12-myristate 13-acetate (PMA) was used as a positive stimulant control. Group
comparisons were analyzed by ANOVA followed by a Tukey’s multiple-comparison test. The asterisks refer to statistical significance: *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001, ****p ≤ 0.0001. Error bars are mean ± SEM values.
such as endotoxin, are another challenge to formulate clinically
safe vaccines (58). Instead, we used extracellular peptides based
on FpvA conjugated to KLH. We observed that vaccination with
FpvA-KLH was as protective as WCV. Differences between the
protection provided by FpvA-KLH peptides and the whole FpvA
protein could be associated with protein conformation, folding,
stability, and solubility. Interestingly, among the four selected
FpvA peptides, FpvA peptide 2 was the most immunogenic
peptide. The efficacy of using FpvA peptide 2 conjugated to KLH
alone or other carrier proteins remains to be further examined.
Vaccine-mediated protection is often conferred by the
production of antigen-specific antibodies that neutralize bacteria
and their toxins to facilitate clearance (59). Vaccination with
FpvA-KLH led to the production of IgM, IgG, and IgA in
serum, and mucosal IgA in the lung. Both IgG from serum
and IgA from lung supernatants were able to recognize lab-
adapted strains as well as CF clinical P. aeruginosa isolates.
We also showed that the antibodies present in serum were
able to mediate opsonophagocytosis and participate in bacterial
clearance in vitro suggesting a potential role for these antibodies
during infection. Similar experiments could not be performed
with lung IgA due to the low concentration of these antibodies
in the samples. Interestingly, we did not find a correlation
between antibody titers (IgM, IgG, or IgA) and bacterial CFU
counts in vaccinated and challenged animals (data not shown).
This may indicate that immunoglobulins alone are not sufficient
to promote the clearance of P. aeruginosa, and that other
components of the immune system have a role in protection.
Additional studies are required to determine the exact role of
antibodies, and in particular IgA, in the mechanism of protection
of this mucosal vaccine.
In this study, we observed a strong cytokine response in
mice challenged with P. aeruginosa, which is characteristic
of infections caused by this bacterium (60, 61). Bacterial
products drive inflammation in the lungs by interacting
with pattern recognition receptors (PRR’s) such as Toll-
like receptors or NOD-like receptors (62, 63). In addition,
the generation of additional bacterial products resulting
from bacterial clearance also promote a pro-inflammatory
response (61). Therefore, even though we observed decrease
in bacterial burden in the FpvA-KLH vaccinated mice, we still
detected a strong acute inflammatory cytokine response in the
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FIGURE 7 | FpvA-KLH vaccine mucosal cellular and humoral immune responses in lung. (A) Lung supernatant IgA antibody titers of NVC (n = 9), and FpvA-KLH (n =
9) vaccinated and challenged mice using unconjugated FpvA peptides as antigen. (B) Detection of IgA binding from lung supernatants to P. aeruginosa lab-adapted (n
= 3) and CF (n = 10) isolates. Each circle represents different P. aeruginosa strains, triangles show the PAO1 strain used for infection. (C) Representative contour plots
of the NVNC (n = 5), NVC (n = 6), and FpvA-KLH (n = 4) groups showing the gating strategy for central memory (TCM), T effector memory-like (TEM), and naïve T cells
(TN). (D) Proportion of naïve T cell population. (E) Proportion of central memory T cells and effector memory-like T cells. (F) Representative gating strategy for
tissue-resident memory T cells (TRM). (G) Proportion of tissue-resident memory cells. Comparisons in (A,B) were performed using an unpaired student t-test. Group
comparisons in (D,E,G) were analyzed by ANOVA followed by a Tukey’s multiple-comparison test. The asterisks refer to statistical significance: *p ≤ 0.05, **p ≤ 0.01,
****p ≤ 0.0001. Error bars are mean ± SEM values.
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lungs. Future studies monitoring the cytokine response and
cellular recruitment of cells over-time from bacterial challenge
to clearance could help assess the differences in between
the groups.
During our histopathology analysis, we observed a strong
recruitment of immune cells to the lung of NVC mice,
accompanied by an increase in lung weight. While this
increase was in part due to the recruitment of neutrophils,
no significant differences were observed in myeloperoxidase
levels by ELISA or immunohistochemistry (data not shown).
Interestingly, the only innate immune cell population that
increased in the lung of FpvA-KLH vaccinated mice was
MHCII+CD45+SiglecF+/−GR1lo/−CD11b+. Among this
population, CD11b+ dendritic cells were the main cell type
increased in FpvA-KLH vaccinated and challenged mice
compared to NVC. One caveat of the flow cytometry analyses
in this study is that mice were not perfused prior to organ
harvest. As a result, there might be low remaining amounts
of circulating blood in the tissue analyzed. To control for this,
we measured the changes in white blood cells in the blood
in response to challenge in vaccinated animals. We did not
observe any significant changes in the proportion of neutrophils
or monocytes in the blood in any of the vaccinated groups
compared to control. For this reason, while we did not perform
perfusions prior to lung single cell analysis, we do not anticipate
that the presence of residual blood in the lung affected the
proportion of cells measured in the lung. Murine lung CD11b+
dendritic cells are potent stimulators of Th17 immunity (64, 65).
IL-17 production in acute pulmonary P. aeruginosa infections
plays a protective role in the innate immune response to
P. aeruginosa and is critical in vaccine-induced protection
(16, 33). We observed that vaccination with FpvA-KLH leads
to a significant increase in Th17T cells and antigen-specific
IL-17 secreting cells in the spleen. This result is not surprising
as we used curdlan, which is known to promote a Th17
immune response (35, 54). Curdlan alone or alum-adjuvanted
FpvA-KLH did not lead to production of an antigen-specific
IL-17 response. This suggests that the combination of the
FpvA-KLH peptides with the adjuvant curdlan is necessary
to produce IL-17 secreting splenocytes. However, the exact
mechanism of the IL-17 response elicited by FpvA-KLH
vaccination and the effect of the adjuvants used requires
further examination.
Intranasal vaccination induces protective systemic and
mucosal humoral and cellular responses in the respiratory tract
(38). After intranasal FpvA-KLH vaccination, we detected a
significant increase in IgA response in the lung supernatant.
This suggests that intranasal FpvA-KLH leads to humoral
mucosal immunity. Previous studies indicate the importance
of a CD4+ tissue-resident memory response for naturally-
acquired immunity against bacterial infections (55). To assess
whether tissue-resident memory cells were present in the lung of
vaccinated animals, we performed flow cytometry to determine
the proportion of TN, TCM, TEM, and TRM cells. We observed
a significant decrease in the proportion of TN cells while the
proportion of TEM increased in FpvA-KLH vaccinated animals
compared to NVNC and NVC controls. These changes might
not be tissue specific and could be in part attributed to residual
blood in the tissue. In addition, we observed that vaccination
with FpvA-KLH leads to a significant increase in CD4+ tissue-
resident memory T cells. Since the markers used in this study
to identify tissue-resident memory T cells are not expressed in
circulating T cells but only in tissue-resident memory T cells,
we do not anticipate that the presence of residual blood in the
tissue influenced the data presented here. Overall, this study
shows the recruitment of tissue-resident memory T cells to the
lung in response to intranasal vaccination; however, the role
of these cells in protection against P. aeruginosa has not yet
been demonstrated.
In this study, we examined the efficacy of FpvA-KLH
vaccination in a murine model of acute pneumonia. The efficacy
of the FpvA-KLH vaccine in the context of CF remains to be
further examined. Unfortunately, the currently available CFTR
mutant CF mice models do not recapitulate CF lung disease (66).
However, the β-ENaC mouse model, which overexpress the β-
subunit of the epithelial sodium channel (ENaC), displays CF-
like clinical lung phenotype (67). In future studies, FpvA-KLH
vaccination will be studied using the β-ENaC mouse model to
evaluate vaccine efficacy on P. aeruginosa-induced lung disease.
Overall, we developed an intranasal peptide-based subunit
P. aeruginosa vaccine using the main iron acquisition receptor
of P. aeruginosa, FpvA, as a vaccine antigen. We observed that
FpvA-KLH vaccination decreased the bacterial burden as well
as lung edema. The FpvA-KLH vaccine was able to induce
antigen-specific humoral and IL-17 immune response as well
as a mucosal adaptive immune response in acute pneumonia.
Taken as a whole, this study demonstrates that the peptide-based
FpvA conjugate vaccine is an effective strategy in mice that could
be used to prevent lung infections caused by P. aeruginosa in
at-risk patients.
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